Netarsudil Mesylate
Brand name: Rhopressa
Rank #212 of 500 drugs by total cost
$65.6M
Total Cost
129,116
Total Claims
$65.6M
Total Cost
2,725
Prescribers
$508
Cost per Claim
28,274
Beneficiaries
201,021
30-Day Fills
$24K
Avg Cost/Provider
47
Avg Claims/Provider
About Netarsudil Mesylate
Netarsudil Mesylate (sold as Rhopressa) was prescribed 129,116 times by 2,725 Medicare Part D providers in 2023, costing the program $65.6M. At $508 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 209 | Treprostinil Diolamine (Orenitram Er) | $68.2M | 5,964 |
| 210 | Esomeprazole Magnesium (Esomeprazole Magnesium) | $66.3M | 964,193 |
| 211 | Dabigatran Etexilate Mesylate (Dabigatran Etexilate) | $66.0M | 220,652 |
| 212 | Netarsudil Mesylate (Rhopressa) | $65.6M | 129,116 |
| 213 | Risperidone Microspheres (Risperdal Consta) | $64.8M | 47,567 |
| 214 | Venlafaxine Hcl (Venlafaxine Hcl) | $64.7M | 2,187,710 |
| 215 | Canagliflozin (Invokana) | $63.7M | 66,550 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology